Methylprednisolone Sodium Succinate for Injection, USP

SECTION 2: Hazards identification

OSHA Carcinogen List Substance IARC NTP OSHA Methylprednisolone Sodium Succinate Not Listed Monobasic Sodium Phosphate Not Listed Sodium Phosphate, Dibasic Not Listed Emergency Overview Methylprednisolone Sodium Succinate for Injection, USP is lyophilized powder in vial and methylprednisolone sodium succinate, an anti- inflammatory glucocorticoid. Clinically, it is indicated for the treatment of a variety of inflammatory and non-inflammatory disorders. In the workplace, this material should be considered potentially irritating to the eyes. Based on clinical use, possible target organs may include the gastrointestinal system, eyes, the nervous system, immune system, endocrine system, and the cardiovascular system. Occupational Exposure Information on the absorption of this product via inhalation or skin contact is not available. Potential Avoid liquid aerosol generation and skin contact. Signs and Symptoms None known from occupational exposures. In clinical use, adverse effects include fluid and electrolyte disturbances, musculoskeletal weakness and myopathy, gastrointestinal disturbances (peptic ulcers), dermatologic reactions (allergic dermatitis), endocrine disturbances (adrenocortical suppression, suppression of growth in children), neurologic disturbances (vertigo, headache, psychosis), and ophthalmic disturbances (glaucoma, cataracts). Prolonged use of methylprednisolone sodium succinate may produce immune suppression, increasing the susceptibility to and masking the symptoms of infections.

Medical Conditions Generally Aggravated by Exposure

Pre-existing hypersensitivity to hydrocortisone sodium succinate or the product ingredients; pre-existing systemic fungal infections, glaucoma, cataracts; endocrine or immune system disorders; pregnancy.